![]() |
|
|
Vol. 280, Issue 2, 941-947, 1997
Departments of
Psychiatry (T.T., K.T.F.),
Pharmacology and
Toxicology (K.T.F.) and
Neuroscience (K.T.F.), University of Utah
School of Medicine and the Veterans Administration Medical Center, Salt
Lake City, Utah
The role of nitric oxide (NO) in the long-term, amine-depleting effects
of methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA)
was investigated in the rodent central nervous system. The NO synthase
inhibitor NG-nitro-L-arginine
methyl ester (L-NAME) antagonized the dopamine- and
serotonin-depleting effects of both METH and MDMA. The protective actions of L-NAME in METH-treated mice were reversed by
prior administration of the NO generator isosorbide dinitrate. However, pretreatment with
NG-monomethyl-L-arginine or
NG-nitro-L-arginine, two other
NO synthase inhibitors, failed to block the neurotoxic effects of METH
or MDMA. L-NAME was also the only NO synthase inhibitor
that antagonized the hyperthermic effects of METH, reducing colonic
temperatures in mice by a mean of 3°C, in comparison with control.
Moreover, if the hypothermic effects of L-NAME in
METH-treated mice were prevented by raising the ambient room
temperature, the dopamine-depleting actions of the stimulant were fully
restored. The latter findings suggest that it is the hypothermic
actions of L-NAME, rather than its NO inhibitory
properties, that are responsible for the prevention of neurotoxicity.
Together with the results of the
NG-monomethyl-L-arginine and
NG-nitro-L-arginine experiments,
the data suggest that NO plays little or no role in the toxic mechanism
of action of METH or MDMA.
This article has been cited by other articles:
![]() |
A. S. Darvesh, B. K. Yamamoto, and G. A. Gudelsky Evidence for the Involvement of Nitric Oxide in 3,4-Methylenedioxymethamphetamine-Induced Serotonin Depletion in the Rat Brain J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 694 - 701. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Jeyarasasingam, M. Yeluashvili, and M. Quik Nitric Oxide Is Involved in Acetylcholinesterase Inhibitor-Induced Myopathy in Rats J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 314 - 320. [Abstract] [Full Text] |
||||